Status:
COMPLETED
Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
Brigham and Women's Hospital
Conditions:
Hodgkin's Disease
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to find out the impact Bleomycin-containing chemotherapy, given with or without chest radiation therapy, on patients' lung function over time.
Detailed Description
* The tests and procedures in this study are part of regular cancer care but this study offers more structured timing of these standard tests. * Due to the potential lung toxicity associated with bleo...
Eligibility Criteria
Inclusion
- Patients with newly diagnosed classical Hodgkin's disease, with mediastinal involvement
- Bleomycin-based chemotherapy alone or in combination with mediastinal irradiation
Exclusion
- Prior chest irradiation
- Mediastinal irradiation received at an outside institution
- Refractory or progressive disease on treatment
Key Trial Info
Start Date :
October 1 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00165438
Start Date
October 1 2001
End Date
January 1 2010
Last Update
December 20 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115